The use of albumin-targeted, multi-functional platinum(IV) prodrugs represents a promising strategy to enhance the intracellular delivery of low-permeability bioactive ligands like 1-MDT and to improve their selective accumulation in tumours, thereby enabling tumour-specific therapy supported by a modulated immune microenvironment. The gene discussed is ALB; the disease is neoplasm.